Bridged oxygen analogs of daunorubcin and doxorubicin
US4826964A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 25, 1986 |
| Grant date | May 2, 1989 |
| Priority date | — |
| Expiry date | Apr 25, 2006 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H15/252
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of the formula ##STR1## wherein R is --COCH.sub.3, --CHOHCH.sub.3, --COCH.sub.2 OH, or --CHOHCH.sub.2 OH; hydrogen; hydroxyl; a 1 to 3 carbon alkyl; a 1 to 3 carbon .omega.-hydroxyalkyl; a 2 to 7 carbon organic acid ester or diester of --COCH.sub.2 OH, --CHOHCH.sub.2 OH, or --CHOHCH.sub.3 ; or the groups --COCH.sub.2 OH, --CHOHCH.sub.2 OH, or --CHOHCH.sub.3 having a 1 to 6 carbon alkyl or aryl ether replacement of one or more hydroxyls; or 13-ketimine derivatives of --COCH.sub.3 or --COCH.sub.2 OH; PA1 Y is methoxy, hydroxy, or hydrogen; and X is O or NH, but when Y is hydroxy or hydrogen, X must be O; PA1 and wherein R' is a 1 to 3 carbon alkyl; and PA1 or wherein Z is O, S, CH.sub.2 or CHOR' wherein R' is 1 to 3 carbon alkyl, PA1 and the pharmaceutically acceptable acid additive salts thereof; are useful for retarding tumor proliferation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.